What this study looked at
CLN2 disease (a form of Batten disease) is a progressive childhood condition, and its main treatment — cerliponase alfa infused into the brain's ventricles — needed evidence on how well it holds up over time. This long-term, open-label extension of the pivotal trial followed treated children for up to five years to assess how durable the benefit is and how safe continued treatment remains.
Key takeaways
- Treatment continued to slow the loss of motor and language function over the long term.
- The safety profile stayed consistent over five years, with management of the infusion device remaining a key practical consideration.
- The data support cerliponase alfa as a sustained, disease-modifying therapy rather than a short-term measure.
Why it matters
These long-term findings give families and health systems the evidence they need when weighing up a lifelong treatment, and reinforce the value of starting early.
